JP5119153B2 - イリノテカン塩酸塩の新規結晶形 - Google Patents

イリノテカン塩酸塩の新規結晶形 Download PDF

Info

Publication number
JP5119153B2
JP5119153B2 JP2008531427A JP2008531427A JP5119153B2 JP 5119153 B2 JP5119153 B2 JP 5119153B2 JP 2008531427 A JP2008531427 A JP 2008531427A JP 2008531427 A JP2008531427 A JP 2008531427A JP 5119153 B2 JP5119153 B2 JP 5119153B2
Authority
JP
Japan
Prior art keywords
irinotecan hydrochloride
irinotecan
iii
pxrd
infrared diffuse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008531427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508874A (ja
JP2009508874A5 (enExample
Inventor
チェン，シュー−ピン
ハーン，ピイン−ジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Singapore Pte Ltd
Original Assignee
Scinopharm Singapore Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Singapore Pte Ltd filed Critical Scinopharm Singapore Pte Ltd
Publication of JP2009508874A publication Critical patent/JP2009508874A/ja
Publication of JP2009508874A5 publication Critical patent/JP2009508874A5/ja
Application granted granted Critical
Publication of JP5119153B2 publication Critical patent/JP5119153B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2008531427A 2005-09-20 2006-09-19 イリノテカン塩酸塩の新規結晶形 Expired - Fee Related JP5119153B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71882705P 2005-09-20 2005-09-20
US60/718,827 2005-09-20
PCT/US2006/036437 WO2007035709A2 (en) 2005-09-20 2006-09-19 Novel crystal forms of irinotecan hydrochloride

Publications (3)

Publication Number Publication Date
JP2009508874A JP2009508874A (ja) 2009-03-05
JP2009508874A5 JP2009508874A5 (enExample) 2009-11-12
JP5119153B2 true JP5119153B2 (ja) 2013-01-16

Family

ID=37889452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008531427A Expired - Fee Related JP5119153B2 (ja) 2005-09-20 2006-09-19 イリノテカン塩酸塩の新規結晶形

Country Status (14)

Country Link
US (1) US7435818B2 (enExample)
EP (2) EP2082741A1 (enExample)
JP (1) JP5119153B2 (enExample)
KR (1) KR101150504B1 (enExample)
CN (1) CN101277694B (enExample)
AR (1) AR056082A1 (enExample)
AT (1) ATE460162T1 (enExample)
AU (1) AU2006292328B2 (enExample)
BR (1) BRPI0616308A2 (enExample)
CA (1) CA2623117C (enExample)
DE (1) DE602006012871D1 (enExample)
ES (1) ES2343204T3 (enExample)
NZ (1) NZ566807A (enExample)
WO (1) WO2007035709A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101318964B (zh) * 2007-06-07 2010-12-15 上海迪赛诺医药发展有限公司 盐酸伊立替康新晶型及其制备方法
US7572803B2 (en) * 2007-10-25 2009-08-11 The Christus Stehlin Foundation For Cancer Research Hydrated crystalline esters of camptothecin
IT1391757B1 (it) * 2008-11-11 2012-01-27 Antibioticos Spa Irinotecan cloridrato cristallino e metodi per la sua preparazione
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
WO2012007952A1 (en) * 2010-07-12 2012-01-19 Hetero Research Foundation Novel polymorph of irinotecan hydrochloride
CN102311443B (zh) * 2011-08-24 2014-07-16 上海北卡医药技术有限公司 盐酸伊立替康的新晶型及其制备方法
CN102617584B (zh) * 2012-03-14 2013-10-16 海南锦瑞制药股份有限公司 一种盐酸伊立替康化合物及其药物组合物
CN102850363B (zh) * 2012-09-18 2013-07-10 山东罗欣药业股份有限公司 盐酸伊立替康化合物及其药物组合物
CA2909642A1 (en) * 2013-04-15 2014-10-23 Regeneron Pharmaceuticals, Inc. Markers of tumor cell response to anti-cancer therapy
CN105713004A (zh) * 2016-03-23 2016-06-29 杭州华东医药集团新药研究院有限公司 一种高品质盐酸伊立替康三水合物晶型的制备方法
US10919905B2 (en) * 2019-05-16 2021-02-16 Scinopharm Taiwan, Ltd. Polymorphism for irinotecan free base

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
DE60314378T2 (de) * 2002-03-01 2008-02-28 Pfizer Italia S.R.L. Kristalline polymorphe form von irinotecanhydrochlorid
CZ20022250A3 (cs) * 2002-06-27 2004-02-18 Pliva-Lachema A. S. Způsob výroby irinotekanu
KR101095382B1 (ko) 2003-02-25 2011-12-16 가부시키가이샤 야쿠르트 혼샤 이리노테칸 염산염의 결정다형의 제조방법
WO2006016203A1 (en) * 2004-08-09 2006-02-16 Shilpa Medicare Limited An improved process for the preparation of irinotecan hydrochloride trihydrate
US20060046993A1 (en) * 2004-09-01 2006-03-02 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
EP1846412B1 (en) * 2005-02-07 2009-10-21 Fermion Oy Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
JP5133704B2 (ja) * 2005-02-08 2013-01-30 フェルミオン オサケ ユキチュア 製造方法

Also Published As

Publication number Publication date
CN101277694A (zh) 2008-10-01
EP1951235B1 (en) 2010-03-10
EP2082741A1 (en) 2009-07-29
BRPI0616308A2 (pt) 2011-06-14
ES2343204T3 (es) 2010-07-26
AU2006292328A1 (en) 2007-03-29
CA2623117A1 (en) 2007-03-29
CN101277694B (zh) 2011-04-20
JP2009508874A (ja) 2009-03-05
NZ566807A (en) 2011-05-27
WO2007035709A2 (en) 2007-03-29
US20070072890A1 (en) 2007-03-29
KR20080059244A (ko) 2008-06-26
AU2006292328B2 (en) 2012-12-20
EP1951235A4 (en) 2008-10-29
WO2007035709A3 (en) 2007-10-25
AR056082A1 (es) 2007-09-19
CA2623117C (en) 2013-12-10
EP1951235A2 (en) 2008-08-06
ATE460162T1 (de) 2010-03-15
US7435818B2 (en) 2008-10-14
DE602006012871D1 (de) 2010-04-22
KR101150504B1 (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
EA015677B1 (ru) СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
EP3456722B1 (en) Crystal forms of crisaborole in free form and preparation method and use thereof
JP5119153B2 (ja) イリノテカン塩酸塩の新規結晶形
BRPI0509595B1 (pt) Processos para a preparação de cristais de forma a e de material de padrão c de bissulfato de atazanavir
HK1211587A1 (en) Process for purifying staurosporine
CN113754596B (zh) 一种吉非替尼的共晶体
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
RU2205830C2 (ru) N-оксиды гетероциклических соединений, обладающие ингибирующей активностью в отношении tnf и pde-iv
US6576647B2 (en) Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
KR101208956B1 (ko) 엘로티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
JPWO2004076460A1 (ja) イリノテカン塩酸塩の結晶多形の製造方法
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
EP1259507B1 (en) Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one hydrochloride
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式，及其制备方法和治疗用途
JP7169695B2 (ja) ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（１）
JP2025518579A (ja) Ｉｒａｋ４阻害剤としてのヘテロシクリルアミドの固体形態
HK40064722A (en) Polymorph of cdk9 inhibitor and preparation method for polymorph and use thereof
WO2022166638A1 (zh) 吲哚衍生物的盐及其用途
CN114835678A (zh) 吲哚衍生物的盐及其用途
CN114989136A (zh) 吲哚衍生物的盐及其用途
KR20080106232A (ko) 베시피르딘 클로하이드레이트의 결정형, 그 제조 방법 및 용도
CN103382177A (zh) 罗氟司特n-氧化物的多晶型物、制备方法和药物组合物
CN106496234A (zh) 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
KR20100125124A (ko) 피타바스타틴 헤미칼슘염의 신규한 결정형 및 그의 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121009

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121022

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5119153

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees